Navigation Links
Change in gene may be underlying molecular defect in some colorectal cancers

Inactivation of a DNA repair gene may be an early step in the development of sporadic colorectal tumors, and detection of the molecular basis for this inactivation may ultimately be useful in risk assessment for colorectal cancer, according to a new study in the September 21 issue of the Journal of the National Cancer Institute.

Cancers can arise from a region of cells with a "field defect", cells that appear normal but that have an underlying molecular defect. The molecular basis for the field defect is easy to understand when tumors develop from cells that all have similar genetic abnormalities, such as those that occur in patients who are genetically predisposed to a cancer or those who undergo an exposure to a carcinogen such as tobacco smoke. However, how the field defect may arise in most sporadic cancers in unclear.

In colorectal cancer, the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is often methylated--that is, the gene's promoter region has methyl groups added to it, which inactivate the gene. Jean-Pierre J. Issa, M.D., of the University of Texas M. D. Anderson Cancer Center in Houston, and colleagues hypothesized that MGMT promoter methylation could be one of the characteristics of the field defect in colorectal cancer, so they studied MGMT promoter methylation in the tumor, adjacent mucosa, and nonadjacent mucosa of 95 colorectal cancer patients and in the colon mucosa of 33 subjects without cancer.

MGMT promoter methylation was found in 50% to 94% of colorectal tumors, depending on the method of detection, and normal-appearing colon mucosa up to 10 cm away from the tumor had detectable MGMT methylation. In addition, the authors detected MGMT methylation in the normal colon mucosa of several subjects who did not have cancer.

"Because a loss of MGMT protein function is a plausible predisposing factor for cancer through the increased occurrence of mutations? our data indicate that MGMT pro moter methylation may qualify as a marker of the field defect in colorectal cancer," the authors write. In addition, "given the high lifetime risk of colorectal tumor development in the U.S. population, it is reasonable to propose testing to determine whether healthy persons with MGMT promoter methylation in normal colorectal mucosa are at higher risk of developing a colon tumor than those without such methylation."

In an editorial, Edward Giovannucci, M.D., Sc.D., of the Harvard School of Public Health, and Shuji Ogino, of Brigham and Women's Hospital, both in Boston, review the concept of the field defect (also called the field effect or field cancerization). They also raise several questions about how these findings may affect related areas of research, such as approaches to chemoprevention and "whether the reversal of DNA methylation in precancerous cells may prevent the development of new primary cancers in the same organ," they write.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Iron Deficiency Sparks Dramatic Changes In Gene Expression
2. Scientists Propose Sweeping Changes to Naming of Bird Neurosystems to Acknowledge Their True Brainpower
3. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4. Some Brain Cells Change Channels To Fine-tune The Message
5. Some Brain Cells Change Channels
6. Methamphetamine Abuse, HIV Infection Cause Changes in Brain Structure
7. Is it Possible to Change Prescribing Habits?
8. Changes to embryos can elicit change in adult fish
9. Changes in amino acids in the 1918 influenza virus cut transmission
10. New mechanism underlying pain found
11. Revealing the machinery underlying the plastic juvenile brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
Breaking Biology News(10 mins):
(Date:2/23/2017)...  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing ... that Linda Marbán, Ph.D, president and chief executive officer, is ... Cowen and Company 37th Annual Health Care Conference ... Boston, MA 29th Annual ROTH ... pm ET) Dana Point, CA ...
(Date:2/22/2017)... ANGELES, CA (PRWEB) , ... February 22, 2017 ... ... today announced that is has acquired Kendall Research Systems, LLC (KRS) ... Technology (MIT) that develops neural interface technology for research and clinical applications. The ...
(Date:2/22/2017)... ON (PRWEB) , ... February 22, 2017 , ... ... on discovery and development of precision treatments for neurodegenerative diseases, today announced it ... validate the ProMIS approach.” This is one of a series of commentaries from ...
(Date:2/22/2017)... Feb. 22, 2017 Aethlon Medical, Inc. (Nasdaq: ... a study that validated the ability of the Aethlon ... with increased mortality in immune-suppressed sepsis patients and also ... The objective of the study was to validate ... Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) ...
Breaking Biology Technology: